Weekly Dose of Optimism #193 · Not Boring by Packy McCormick
Science, Technology & Innovation · May 15, 2026
Cowboy Space Corp. (formerly Aetherflux) embeds the orbital data center into the rocket upper stage—turning the launch vehicle into the compute payload—forcing extreme vertical integration, direct competition with launch providers like SpaceX, and shifting investor focus from software scaling to manufacturing, launch economics, and capital intensity.
Weekly Dose of Optimism #193 · Not Boring by Packy McCormick
Health & Medicine · May 15, 2026
Daraxonrasib’s Phase 3 trial in metastatic pancreatic cancer showed that an oral, once-daily molecular-glue RAS inhibitor roughly doubled median survival to 13.2 months, demonstrating that chemistry which converts historically undruggable RAS proteins into druggable targets can materially expand the treatable proteome and platform value.
Weekly Dose of Optimism #193 · Not Boring by Packy McCormick
Business, Finance & Industries · May 15, 2026
Varda’s deal with United Therapeutics moves the company from proving spacecraft operations to testing microgravity-enabled drug manufacturing—starting with lung-disease molecular samples—to validate in-space pharmaceutical development with a major incumbent, potentially proving superior drug forms and accelerating credibility despite no immediate revenue certainty.
Weekly Dose of Optimism #193 · Not Boring by Packy McCormick
Business, Finance & Industries · May 15, 2026
Public markets are re-opening a tech liquidity cycle—strong IPO pricing and aftermarket gains (e.g., Cerebras, Fervo) are returning capital to LPs and enabling more venture funding for hardware and energy, changing financing strategies even as markets show froth.
Weekly Dose of Optimism #193 · Not Boring by Packy McCormick
Business, Finance & Industries · May 15, 2026
Isomorphic Labs raised $2.1B in a Series B to shift from AI-drug-design benchmark wins to funding clinical development—using its IsoDDE engine (which reportedly outperformed AlphaFold 3 on protein–ligand benchmarks and rediscovered cereblon’s second binding pocket from sequence alone) to push its first wholly-owned candidate into human trials by year-end and signal a market shift toward financing teams that integrate model performance, proprietary pipelines, and clinical execution.